Topics

FDA Approves Entrectinib for NTRK+ Tumors and ROS1+ NSCLC

16:29 EDT 15 Aug 2019 | OncLive

The FDA has granted an accelerated approval to entrectinib for the treatment of adult and pediatric patients ≥12 years of age with solid tumors that harbor a NTRK fusion, and has also approved the agent for the treatment of adults with ROS1-positive, metastatic non–small cell lung cancer.

Original Article: FDA Approves Entrectinib for NTRK+ Tumors and ROS1+ NSCLC

NEXT ARTICLE

More From BioPortfolio on "FDA Approves Entrectinib for NTRK+ Tumors and ROS1+ NSCLC"

Quick Search

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Pediatrics
Pediatrics is the general medicine of childhood. Because of the developmental processes (psychological and physical) of childhood, the involvement of parents, and the social management of conditions at home and at school, pediatrics is a specialty. With ...